- Home
- PASG
PASG
Passage Bio Inc.
as 11-15-2024 4:00pm EST
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 42.2M | IPO Year: | 2020 |
| Target Price: | $13.00 | AVG Volume (30 days): | 229.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $1.79 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Passage Bio Inc. (PASG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Sep 19 '24 | Sell | $0.71 | 39,300 | $27,903.00 | 7,794,569 |
Latest Passage Bio Inc. News
PASG Breaking Stock News: Dive into PASG Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
Passage Bio Achieves Milestones in Gene Therapy Trials
GlobeNewswire
4 days ago
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
11 days ago
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
GlobeNewswire
24 days ago
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
GuruFocus.com
2 months ago
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc
GuruFocus.com
2 months ago
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc
GlobeNewswire
2 months ago
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
GlobeNewswire
2 months ago
Passage Bio Welcomes Tom Kassberg to Board of Directors
Compare PASG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PASG Passage Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.